Biologics Certificate of Analysis …dmsic.moph.go.th/dmsic/admin/files/userfiles/files/D2S2......
Transcript of Biologics Certificate of Analysis …dmsic.moph.go.th/dmsic/admin/files/userfiles/files/D2S2......
www.mahidol.ac.th
1
Certificate of Analysis for Biologics: Quality Attribute Characterization and Specifications for Biologic Products
Assist. Prof. Dr. Jiraphun JittikoonDepartment of Biochemistry
Faculty of Pharmacy, Mahidol University
Assist. Prof. Dr. Jiraphun JittikoonDepartment of Biochemistry
Faculty of Pharmacy, Mahidol University
www.mahidol.ac.th
Biologics
� Human-derived Biologics (Plasma-derived Biologics)
� Biotechnology-derived Biologics
www.mahidol.ac.th
3
Biologics: Molecular Complexity
www.mahidol.ac.th
4
Proteins have expected:
• Size, charge, hydrophobicity
• Correct folding (S-S bonds)
• Subunits
• Glycosylation
• Bioactivity
& Unexpected:
• Aggregation (side effects)
• Incorrect folding
• Amino acid modifications
– ox, deam, cys
• Truncation, proteolysis
Biologics: Molecular Complexity
www.mahidol.ac.th
5
Small Molecule Medicines vs. Biological Medicines
www.mahidol.ac.th
Biological Medicines vs. Biological Medicines
www.mahidol.ac.th
7
The following points should be taken into consideration when establishing scientifically justifiable specifications.
� Specifications are linked to a manufacturing process.
� Specifications should account for the stability of drug substance and drug product.
� Specifications are linked to preclinical and clinical studies.
� Specifications are linked to analytical procedures
Specification for Biologic Productswww.mahidol.ac.th
Biologics: Biotechnology-derived Biologics
www.mahidol.ac.th
Chemistry, Manufacturing and Control Issues in Production of
Therapeutic Biologic Protein Products
Chemistry, Manufacturing and Control Issues in Production of
Therapeutic Biologic Protein Products
9
Drug Substance and Drug Product Characterization
Critical Quality Attribute
www.mahidol.ac.th
Quality control of biologics
www.mahidol.ac.th
11
Analytical Methods and Reference Standards www.mahidol.ac.th
Quality control of biologics
www.mahidol.ac.th
Quality control of biologics
www.mahidol.ac.th
Quality control of biologics
www.mahidol.ac.th www.mahidol.ac.th
Drug Substance Characterization
� Safety� Ensured by the specified limits for bioburden and endotoxin, misc.
process-related contaminants
� Purity & Characterization � process-related impurities (e.g., endogenous viruses, host-cell
proteins, DNA, leachables, anti-foam, antibiotics, toxins, solvents, heavy metals, etc.)
� Product-related impurities (e.g., aggregates, breakdown products, product variants due to: oxidation, deamidation, denaturation, loss of C-term Lys in MAbs etc.)
� Product substances (product variants that are active)
16
www.mahidol.ac.th
Drug Substance Characterization� Identity
� Unique for protein of interest, especially relevant for closely related proteins manufactured in the same facility
� Potency� Required to assess biological activity of the product � Assay should be relevant for protein mechanism of action
� Strength� Protein content
� Stability� Drug Substance stability should be demonstrated with appropriate
stability-indicating assays
17
www.mahidol.ac.th
Drug Product Characterization
� Safety� Final Drug Product for injection should be sterile within specified limits
for endotoxin � Immunogenicity should be screened and monitored
� Purity & Characterization � Product and process-related impurities & product-related substances
should be within specified limits
� Identity� Unique for protein of interest, especially relevant for closely related
proteins manufactured in the same facility
18
www.mahidol.ac.th
� Potency� Assay should be relevant for protein mechanism of action
� Strength� Protein content
� Stability� Drug Product should maintain stability for the duration of the clinical
trial
� Container closure compatibility� Primary function - barrier to microbial ingress � Extractables/Leachables studies
Drug Product Characterization
19
www.mahidol.ac.th
Methodology for Characterization
• Safety– LAL test, rabbit pyrogen test, bacterial culture methods
• Purity & Characterization including but not limited to:– Reversed-phase HPLC, Peptide mapping, MS – SDS-PAGE, Western analysis, capillary electrophoresis– SEC, AUC, FFF, light scattering– Ion Exchange Chromatography – Carbohydrate analysis (capillary electrophoresis, HPAEC = high-pH anion-
exchange chromatography, IEF for sialic acid)
20
www.mahidol.ac.th
Methodology for Characterization
• Identity– N-terminal sequencing– Peptide mapping – Immunoassays (ELISA, Western blotting)
• Potency– Animal-based assays, cell-based assays, reporter gene, biochemical (e.g.,
enzyme activity)
• Protein content– RIA, ELISA, UV absorbance, Bradford
21
www.mahidol.ac.th
22
PRINCIPLES FOR CONSIDERATION IN SETTING SPECIFICATIONS
� Characterization� Physicochemical properties� Biological activity� Immunochemical properties� Purity, impurities and contaminants� Quantity
� Analytical Considerations� Reference standards and reference materials� Validation of analytical procedures
� Process Controls� Process-related considerations� In-process acceptance criteria and action limits� Raw materials and excipient specifications
� Pharmacopoeial Specifications� Release Limits vs. Shelf-life Limits� Statistical Concepts
www.mahidol.ac.th
23
Specification for Biologic Products
� Drug Substance Specification� Appearance and description� Identity� Purity and impurities� Potency� Quantity
� Drug Product Specification� Appearance and description� Identity� Purity and impurities� Potency� Quantity� General tests� Additional testing for unique dosage forms
www.mahidol.ac.th
24